Susan Bobulsky Sells 1,195 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Posted by George Bondi on Sep 19th, 2026

Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) insider Susan Bobulsky sold 1,195 shares of the company’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $27.00, for a total transaction of $32,265.00. Following the completion of the sale, the insider directly owned 395,794 shares in the company, valued at $10,686,438. This trade represents a 0.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Susan Bobulsky also recently made the following trade(s):

On Monday, August 10th, Susan Bobulsky sold 3,000 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.00, for a total value of $75,000.00.
On Thursday, July 30th, Susan Bobulsky sold 1,299 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $24.00, for a total value of $31,176.00.
On Wednesday, July 1st, Susan Bobulsky sold 487 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $22.00, for a total value of $10,714.00.

Adaptive Biotechnologies Price Performance

Shares of NASDAQ ADPT opened at $28.61 on Friday. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.79 and a quick ratio of 4.68. The stock has a market capitalization of $4.57 billion, a price-to-earnings ratio of -69.78 and a beta of 2.09. The firm’s 50 day simple moving average is $24.36 and its 200-day simple moving average is $18.65. Adaptive Biotechnologies Corporation has a 12 month low of $12.00 and a 12 month high of $28.72.

Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The firm had revenue of $71.55 million for the quarter, compared to analysts’ expectations of $65.44 million. During the same period last year, the company posted ($0.17) earnings per share. The business’s quarterly revenue was up 21.5% on a year-over-year basis. Analysts expect that Adaptive Biotechnologies Corporation will post -0.4 EPS for the current year.

Institutional Investors Weigh In On Adaptive Biotechnologies

Large investors have recently bought and sold shares of the company. Arizona State Retirement System raised its holdings in shares of Adaptive Biotechnologies by 1.3% during the second quarter. Arizona State Retirement System now owns 31,866 shares of the company’s stock valued at $684,000 after acquiring an additional 416 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Adaptive Biotechnologies by 6.8% in the first quarter. PNC Financial Services Group Inc. now owns 14,737 shares of the company’s stock worth $205,000 after acquiring an additional 941 shares during the last quarter. Assetmark Inc. increased its position in shares of Adaptive Biotechnologies by 46.4% during the first quarter. Assetmark Inc. now owns 4,421 shares of the company’s stock worth $61,000 after purchasing an additional 1,401 shares in the last quarter. Nykredit A S purchased a new stake in shares of Adaptive Biotechnologies during the second quarter worth approximately $31,000. Finally, EverSource Wealth Advisors LLC increased its position in shares of Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after purchasing an additional 1,565 shares in the last quarter. 99.17% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. BTIG Research lifted their price target on Adaptive Biotechnologies from $24.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Friday, July 17th. Guggenheim boosted their price objective on Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Morgan Stanley increased their target price on Adaptive Biotechnologies from $20.00 to $22.00 and gave the company an “equal weight” rating in a research report on Thursday, July 30th. Finally, Piper Sandler lifted their price target on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Adaptive Biotechnologies presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.42.

View Our Latest Stock Report on Adaptive Biotechnologies

About Adaptive Biotechnologies

(Get Free Report)

Adaptive Biotechnologies Corp. (NASDAQ: ADPT) is a biotechnology company focused on applying immune-system data to the diagnosis and treatment of disease. The company develops technologies that decode T-cell and B-cell receptors, helping researchers and clinicians analyze the adaptive immune response at the scale of individual immune cells.

Its key products include clonoSEQ, a clinical diagnostic test that measures minimal residual disease in certain blood cancers, including multiple myeloma and acute lymphoblastic leukemia.